What is Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (600572.SS) StockRank?

MoatMap's StockRank for Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) is 94/100, with a Strong Buy signal. This is a composite score combining Quality (69), Value (58), and Momentum (59) factor ranks across MoatMap's 20,000+ stock universe.

Does Zhejiang CONBA Pharmaceutical Co.,Ltd. have an economic moat?

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Zhejiang CONBA Pharmaceutical Co.,Ltd. in?

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600572.SS

STRONG BUYREMOVE

Zhejiang CONBA Pharmaceutical Co.,Ltd. · Healthcare · China · $1.6B · Avg Vol: $20M/d

StockRank

P/E (TTM)

21.8x

ROE

6.9%

D/E

0.0x

Dividend %

3.6%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Zhejiang CONBA Pharmaceutical is a domestic Chinese drug manufacturer. It does not operate as a global CDMO and lacks the high-barrier regulatory moats we look for in healthcare compounders.

COMPANY DESCRIPTION

Zhejiang CONBA Pharmaceutical Co., Ltd. researches, manufactures, and markets modern Traditional Chinese Medicine, chemical drugs, and health products. The company possesses a diverse portfolio of well-known OTC and prescription brands, with strong distribution channels across Chinese retail pharmacies. It is a leading, state-backed pharmaceutical group with a balanced focus on self-medication and clinical therapies.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	887M	995M	963M	957M	2.6%
EPS	0.02	0.03	0.04	0.03	10.7%
Shares	2.6B	2.6B	2.6B	2.5B	-1.4%
Debt	177M	153M	63M	45M	-36.7%
Equity	1.0B	1.0B	1.0B	1.0B	0.6%
Op CF	171M	133M	150M	139M	-6.6%
Inv CF	-31M	-43M	-31M	-10M	—
Fin CF	-137M	-106M	-283M	-73M	—

PRICE (1M)-6.6%

SMA 50SMA 200

$0.61

RSI (14)

36.6

52W High

$0.76

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

8.7%69.2

ROE

6.9%62.2

GP/Assets

36.0%74.7

Op. Margin

13.4%72.3

FCF/Assets

4.6%69.1

Piotroski

—83.4

Int. Cover

50.0x91.5

D/E Ratio

0.02x82.4

Current Ratio

1.98x36.7

Value

P/E (TTM)

21.8x52.5

EV/EBITDA

10.7x40.3

P/FCF

159.2x50.9

P/B

1.5x67.4

P/S

1.6x74.3

Div Yield

3.6%79.4

Momentum

52W High %

80%73.1

RS 6M

-21%56.1

SMA 50/200

0.97x53.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—62.2

Q Growth

5%44.9

FUNDAMENTALS

Market Cap

$1.6B

P/E (Forward)

13.0x

Gross Margin

53.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600572.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600572.SS	Zhejiang CONBA Pharmaceutical Co.,Ltd.(you)	$1.6B	94	STRONG BUY
600267.SS	Zhejiang Hisun Pharmaceutical Co., Ltd.	$1.8B	95	STRONG BUY
600285.SS	Henan Lingrui Pharmaceutical Co., Ltd.	$1.8B	96	STRONG BUY
600211.SS	Tibet Rhodiola Pharmaceutical Holding Co.	$1.8B	96	STRONG BUY
1681.HK	Consun Pharmaceutical Group Limited	$1.5B	98	STRONG BUY
600993.SS	Mayinglong Pharmaceutical Group Co., Ltd.	$1.5B	87	STRONG BUY
600216.SS	Zhejiang Medicine Co., Ltd.	$1.8B	89	STRONG BUY
600750.SS	China Resources Jiangzhong Pharmaceutical Co.,Ltd	$2.4B	94	STRONG BUY
002275.SZ	Guilin Sanjin Pharmaceutical Co., Ltd.	$1.2B	96	STRONG BUY
605507.SS	Guobang Pharma Ltd.	$1.8B	86	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) — Stock Score Summary

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) has a MoatMap StockRank of 94/100 based on Quality (69/100), Value (58/100), and Momentum (59/100) factor scores. The current signal is STRONG BUY. Zhejiang CONBA Pharmaceutical is a domestic Chinese drug manufacturer. It does not operate as a global CDMO and lacks the high-barrier regulatory moats we look for in healthcare compounders.

Key Financial Metrics

Price	$0.61
Market Cap	$1.6B
P/E (TTM)	21.84
P/E (Forward)	12.97
Price/Book	1.45
Return on Equity	6.9%
Return on Invested Capital	8.7%
Debt/Equity	2.04
Gross Margin	53.5%
Operating Margin	13.4%
Revenue Growth	13.1%
Dividend Yield	3.6%
Free Cash Flow	$10M

Zhejiang CONBA Pharmaceutical Co.,Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Zhejiang CONBA Pharmaceutical Co.,Ltd.’s (600572.SS) StockRank?: MoatMap’s StockRank for Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) is 94/100, with a Strong Buy signal. It is a composite of Quality (69), Value (58), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does Zhejiang CONBA Pharmaceutical Co.,Ltd. have an economic moat?: Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Zhejiang CONBA Pharmaceutical Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Zhejiang CONBA Pharmaceutical Co.,Ltd. in?: Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).